TIDES Europe: Oligonucleotide and Peptide Therapeutics is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Informa

James Heyes, PhD
SVP, Technology Development at Genevant Sciences

Profile

Dr James Heyes serves as Genevant’s SVP of Technology Development, and has worked in the field of nucleic acid delivery and LNP design for over 20 years. Prior to Genevant, he spent 17 years at Protiva, Tekmira Pharmaceuticals and Arbutus Biopharma, covering early discovery to pharmaceutical development of the LNP platform. He designed the lipid components enabling the first demonstration of RNA interference in primates, and subsequently the advance of 13 clinical candidates. James holds a PhD in Medicinal Chemistry from the Institute of Cancer Research in London, UK.

James Heyes, PhD's Network

Agenda Sessions

  • Strategies for the Delivery of Nucleic Acid Therapeutics

    , 16:30